Daichi Sankyo remains a Buy, despite recent setbacks in its Trop2-directed ADC for lung cancer. DSKYF continues to advance its pipeline, offering positive catalysts over the next year. Recent financials and pipeline updates reinforce conviction in the investment thesis at current levels.

The Fed is expected to cut interest rates in a few days. The rate cuts are a strong catalyst for the REIT sector. I highlight two REITs that have a lot to gain from this.

BEIJING--(BUSINESS WIRE)-- #Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollm.

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to be generally well-tolerated with a manageable safety profile LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at 8:00 a.m. EST LAUSANNE, Switzerland , Dec. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

U.S. equity markets dipped in a volatile week, while benchmark interest rates pulled back from one-month highs, as renewed anxiety over stretched AI-driven valuations collided with mounting monetary policy uncertainty. Public commentary from Fed officials revealed an unusually fractured committee, with a divide that was deepened further by a mixed slate of employment data via the long-delayed September payrolls report. Payrolls data showed that the U.S. economy added 119k jobs in September- better than estimates- but prior months were revised lower and the unemployment rate rose to four-year highs.

Agree Realty Corporation is a financially robust REIT with a $9.08B asset base, investment-grade ratings, and a 30-year dividend history. ADC.PR.A preferred stock offers a 5.88% yield, outperforming ADC's unsecured bonds, and features cumulative dividends and a short duration to call in 2026. ADC.PR.A's BBB-/BBB/Baa2 ratings and strong financial metrics make it an appealing choice for conservative, risk-averse investors seeking stable income.

Most dividend stocks only pay investors on a quarterly basis. Most corporate bonds and government Treasury bonds only pay interest payments semi-annually. Passive income paid monthly is a perfect way to help with monthly expenses and other costs.

Agree Realty delivered another strong, consistent quarter, with results slightly exceeding expectations and full-year AFFO guidance raised again. ADC's disciplined approach, high-quality tenants, and strategic acquisitions underpin its reliable performance, highlighted by $451 million invested in Q3 2025. The company remains selective with equity issuance, aligning funding with acquisitions and maintaining a robust pipeline of unsettled forward shares for future growth.

Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations. Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as with industry leaders and pioneers at CPHI in Frankfurt, Defence is moving forward with the strategy to become a supplier of its Accum® platform technology to ADC companies struggling with dosing and toxicity as well as to improve the drug delivery precision to cancer cells more effectively for the benefit of cancer patients.

TYSONS, Va.--(BUSINESS WIRE)--Alarm.com (Nasdaq: ALRM), the leading platform for intelligently connected properties, launches the ADC-V730, the company's first Wi-Fi spotlight camera. The V730 combines vivid 4MP video resolution with spotlight-enabled color night vision and proactive deterrence features to create a first line of defense against unwanted activity. Built-in Video Analytics on the V730 detect people, animals, or vehicles, triggering the integrated spotlight to automatically illumi.